TriangleTREATMENT READING
Indolent B-Cell Non-Hodgkin Lymphoma
Choose a source section by treatment, subtype or setting. Patient and professional reading are labelled separately.
Selected text from the National Cancer Institute, with original links and dates. This Triangle reading page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
13 studies cited in this topic · see design and results →
Explore 5 related disease and treatment settings → · Source-derived catalogue; clinical review pending.
Late Effects of Treatment of NHL
Therapeutic approaches
Therapeutic approaches
Treatment Option Overview for Indolent B-Cell Non-Hodgkin Lymphoma
Treatment of Indolent Stage I and Indolent, Contiguous Stage II B-Cell Non-Hodgkin Lymphoma
Treatment Options for Indolent Stage I and Indolent, Contiguous Stage II B-Cell NHL
Radiation therapy
Rituximab with or without chemotherapy
Watchful waiting
Other therapies as designated for patients with advanced-stage disease
Treatment of Indolent, Noncontiguous Stage II/III/IV B-Cell Non-Hodgkin Lymphoma
Treatment Options for Indolent, Noncontiguous Stage II/III/IV B-Cell NHL
Watchful waiting for asymptomatic patients
Rituximab alone or in combination with cytotoxic agents used in front-line therapy
Lenalidomide and rituximab
Maintenance rituximab
Obinutuzumab alone or in combination with cytotoxic agents used in front-line therapy
Treatment of Indolent, Recurrent B-Cell Non-Hodgkin Lymphoma
Treatment Options for Indolent, Recurrent B-Cell NHL
Rituximab alone or in combination with cytotoxic agents used in front-line therapy
Obinutuzumab alone or in combination with cytotoxic agents used in front-line therapy
Lenalidomide and rituximab
Zanubrutinib and obinutuzumab
EZH2 inhibitor
Tazemetostat
Bispecific T-cell engagers
Mosunetuzumab
Epcoritamab
Chimeric antigen receptor (CAR) T-cell therapy
Stem cell transplant
Palliative radiation therapy
Therapeutic options
Preserved source evidence · Independent clinical review pending · Not medical advice